Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biology, ethical sourcing, and manufacturing profile of human trophoblast stem cells. In Part 2, the conversation shifts to the larger ambition: using those cells not just to treat disease, but to slow, stop, or reverse biological aging itself. The evidence starts with a striking finding from the National Institute on Aging, and it builds from there.

Topics discussed:

• The science and ethics of sourcing stem cells from ectopic pregnancies (03:02)
• Differences in differentiation potential between very early-stage cells and traditional MSCs or iPSCs (05:09)
• The origins of the research focus, driven by NIH/NIA inquiry and lessons from Stanford parabiosis studies (07:27)
• Explanation of senescent cells, inflammation, and disease connections (08:51)
• Potential therapeutic scope, from neurodegeneration to autoimmune diseases, and systemic anti-inflammatory applications (09:26)
• Vision for aging prevention—possibility of maintaining young biological age through regular secretome therapy (10:21)
• Challenges and global differences in regulation, access, and clinical adoption (12:05)
• The realistic limits and potential for reversing versus preventing age-related damage (13:20)
• The future landscape of cell and gene therapy in medicine (14:20)
• Why more investment is needed in longevity science and therapeutics (16:25)
• Practical takeaways for listeners about improving healthspan and longevity today (18:07)

Smart insight:

Prevention is becoming the new frontier of medicine, shifting from treating disease to preserving long-term biological function. Yuta Lee highlights a future where proactive longevity strategies, from lifestyle choices to emerging biotech, could keep us healthier for longer and push toward “escape velocity” against aging.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

• Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
• Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
• Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
• Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?

Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly that insight. Human trophoblast stem cells, sourced from ectopic pregnancy tissue that is otherwise discarded, sit at a unique biological intersection: earlier than MSCs, free from the ethical barriers of embryonic stem cells, expandable to 85 population doublings, and naturally equipped with HLA-G immune modulation that opens the door to allogeneic, off-the-shelf therapy at scale.

Topics discussed

• Common misconceptions and challenges in bioprocess development for biological therapeutics (02:45)
• The origin story behind Yuta Lee's interest in stem cells, including his father’s surgical discovery (04:15)
• A look at the intellectual property strategy that protected and enabled Yuta Lee's company to develop its platform (07:26)
• A clear explanation of different stem cell types (embryonic, trophoblast, mesenchymal, adult, and induced pluripotent) and their sources (09:37)
• Ethical and regulatory issues involved in sourcing stem cells, and how trophoblast cells offer a unique alternative (10:59)
• Discussion of stem cell differentiation, population doubling, and scalability for manufacturing purposes (17:03)
• Importance of immune privilege and HLA-G expression in pre-placental cells for off-the-shelf therapies (20:20)
• Shifts in the industry from autologous to allogeneic therapies, and the role trophoblast cells may play in future treatments (22:00)

In Part 2, Yuta Lee goes into the science of biological aging, the senescent cell secretome findings from the National Institute on Aging, and what a prevention-first therapeutic approach to healthspan extension could look like in practice.

Smart insight:

The scalability ceiling of MSCs is not just a manufacturing inconvenience, it is a strategic constraint. At 25 to 30 population doublings from birth-derived donors, every new donor batch requires revalidation as a distinct biological starting material. Trophoblast stem cells at 85 doublings from a single donor change that equation fundamentally, making true allogeneic scale not just biologically possible but manufacturable.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

• Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
• Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
• Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
• Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?

In this episode, David Brühlmann, host of the Smart Biotech Scientist Podcast, reveals how traditional "one factor at a time" screening in biosimilar development can take over 12 months, while the parallel group design massively accelerates discovery by grouping up to five factors per experiment and applying a multivariate analysis pipeline.

Topics discussed:

• The limitations of traditional and large DoE designs and the advantages of parallel group design (00:08)
• Best practices for grouping compounds by biological mechanism with four essential rules (00:53)
• The importance of anchor compounds, separating strong modulators, and initial univariate screens for unknown compounds (01:43)
• Guidance on managing practical issues, including evaporation, liquid handling, osmolality, and replicating production processes (06:42)
• The use of multivariate analysis tools: Principal Component Analysis, Mahalanobis distance, and decision trees for candidate selection (10:14)
• Key results and outcomes from applying the parallel group method, including faster and more cost-effective quality modulator identification (12:46)
• Three improvements David would recommend today: prequalifying compounds, broader quality analytics, and hybrid modeling integration (13:49)
• The shift in mindset from “time problem” to “information problem” in process development (16:50)
• Extending the parallel group and multivariate approach to other areas like clone selection and scale-up decisions (17:52)

Smart insight:

Process development is fundamentally about generating actionable information, not just running more experiments. The parallel group, multivariate pipeline lets teams ask better questions, in parallel, with dramatically improved data yield. This mindset and methodology extend well beyond biosimilar media development into clone selection, feed design, and process characterization, wherever complexity would paralyze traditional approaches.

If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.

If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.

• Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
• Episodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl
• Episodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint
• Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.

Support the show

Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing progress and risking critical quality attributes in monoclonal antibody development.

David Brühlmann breaks down a practical, parallel framework for rapid compound screening that addresses interaction effects, masking, and data quality. Methods proven in challenging biosimilar development programs.

Topics discussed:

• The historical bottleneck of one-at-a-time screening in drug discovery and the impact of high throughput methods (01:04)
• Problems with both one-factor-at-a-time and large design of experiments approaches when handling many variables (02:10)
• Description of the parallel group method: splitting 17 quality modulating compounds into five biologically relevant groups and running experiments in parallel (06:09)
• How grouping compounds by biological mechanism improves interpretability and experimental design (06:43)
• Strategies for minimizing dilution effects, toxicity risks, and masking in multi-factor screens (08:24)
• The importance of multivariate analysis: using principal component analysis (PCA), Mahalanobis distance, and decision trees to interpret and select optimal experimental conditions (10:31)
• Real-world outcomes: identifying optimal compound combinations in just two rounds of screening (15:20)
• Reflections on the evolving role of hybrid modeling and machine learning in biosimilar process optimization (15:54)

In Part 2, the focus shifts to a hands-on approach, covering how to design compound groups based on biology, set concentration ranges without compromising data quality, and execute a 96-well screen with the rigor the method demands. It also highlights three key aspects that would be approached differently if the study were conducted today.

Strategic insight:

Effective compound screening shifts from one-at-a-time testing to biology-driven parallel grouping combined with multivariate analytics, enabling faster identification of optimal combinations while preserving data quality and capturing interaction effects.

If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.

If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.

• Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
• Episodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl
• Episodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint
• Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.

Support the show

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufacturing model built around clinical proximity, the global alliance bringing TIL production to regions with no current access, and the next-generation engineered approaches redefining what these therapies can do.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. If you missed Part 1, she explained how specific activation changes recovered a failing TIL process from 50% to 95% success in heavily pre-treated patients.

Topics discussed:

• How close collaboration with MD Anderson accelerates clinical development and regulatory readiness (03:08)
• CTMC’s approach to process development and adapting to innovative technologies (05:15)
• The value of partnership-based models versus traditional CDMO-driven approaches (06:24)
• Global technology transfer: building alliances to expand access to cell therapies, with a case study in Brazil (07:35)
• Key barriers and solutions for cell therapy manufacturing in new regions (09:41)
• Practical advice for scientists starting in GMP manufacturing and process development (10:46)
• Future directions in CAR T and TIL, including logic-gated CARs, engineered TILs, and in vivo therapies (12:24)
• The importance of continued innovation and collaboration to expand global patient access (17:39)

Smart insight:

The choice of manufacturing partner in cell therapy is not a logistics decision. It is a process development decision. CTMC's collaboration-based model exists because many early-stage developers arrive without a process robust enough to hand over. For scientists in small or mid-sized companies, engaging that kind of partnership too late, or on purely transactional terms, is one of the most avoidable risks in early clinical development.

If you’re interested in exploring further the concepts we touched on, such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

• Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
• Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
• Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the hard way, watching the same manufacturing process succeed brilliantly with one donor and fail completely with the next. In this episode, she explains why starting material variability is the defining challenge of cell therapy manufacturing, and what it actually takes to build a process robust enough to survive it.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. She holds a PhD in immunology and has spent two decades advancing T cell therapy from early research programs at MD Anderson to GMP-compliant clinical manufacturing. She holds four patents in adoptive cell therapy.

Key topics discussed:

• Personal journey: from immunology PhD in Quebec to cell therapy leadership in Houston (04:25)
• Evolution of TIL therapy at MD Anderson, including manufacturing innovations to overcome declining T cell yields (06:14)
• The fundamental differences between traditional medicines and cell-based immunotherapies (10:01)
• Unique manufacturing complexities for autologous therapies, including batch variability and process standardization (11:19)
• Strategies to address decreased cell fitness in heavily pretreated patients, including changes in cell activation and culture conditions (13:57)
• Key learnings from the CAR T and TIL manufacturing process: balancing process duration, cell fitness, and product yield (16:28)
• Mechanistic differences between CAR T and TIL therapies and their implications for efficacy and resistance (17:58)
• The limits and risks of automation in cell therapy manufacturing—balancing manual vs. automated processes (24:04)
• Why moving between manufacturing platforms raises challenges in comparability and clinical outcomes (25:44)
• The ongoing search for critical cell quality attributes that correlate with patient response (27:00)

In part two, Chantale goes deeper into next-generation approaches, technology transfer, and what needs to change to broadly expand patient access.

Smart insight: In cell therapy, manufacturing isn’t just a production step. It defines the therapy itself. Because each patient’s starting cells are unique, even subtle changes in the process can significantly alter clinical outcomes.

If you’re interested in exploring further the concepts we touched on—such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

• Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
• Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
• Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.

Ron Najafi knows what rigorous analytical work actually looks like under pressure. As founder and CEO of Emery Pharma, he led the investigation that identified NDMA as a degradation product of ranitidine — findings the FDA formally validated and that reshaped how the industry approaches nitrosamine risk assessment. In Part 2, he moves from that scientific foundation into the operational questions that determine whether a CRO partnership accelerates your program or quietly slows it down.

If you haven't heard Part 1, it covers Ron's career arc and the technical details of nitrosamine contamination in pharmaceutical development. This episode stands on its own for anyone focused on CRO selection, bioanalytical strategy, and what three decades of building analytical companies actually teaches you.

Topics discussed:

• How to tell if a CRO’s workflow is robust—or just rigid (05:51)
• The importance of method validation and product stability testing (07:27)
• Managing expectations and trust-building in client relationships (08:29)
• Entrepreneurial lessons: raising capital, team-building, and finding the right partners (10:00)
• The hidden costs of public vs. private biotech ventures (12:31)
• Reducing bioanalytical costs in biologics through mass spectrometry (13:23)
• The future of analytical workflows and personalized medicine (14:48)

Smart insight:

In biotech, success isn’t just about the science—it’s about strategic discipline. Ron emphasizes a few hard-earned principles: raise more capital than you think you’ll need, don’t fixate on valuation, and invest in smart, creative talent. Just as important, real value is unlocked through strong partnerships and the ability to manage collaborations and acquisitions with intention.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

• Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 139 - 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Support the show

When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.

Ron Najafi has lived that reality firsthand. As founder of NovaBay Pharmaceuticals and Emery Pharma, he spent decades building companies at the intersection of analytical chemistry and drug development. His investigation into nitrosamine contamination in ranitidine — which led the FDA to formally validate Emery Pharma's findings — remains one of the most consequential episodes in recent pharmaceutical quality history.

In Part 1, Ron traces the scientific and entrepreneurial path that led him there, and shares what CMC teams working in drug development need to understand about impurity risk before it becomes a regulatory crisis.

Episode highlights:

• Early academic experiences and inspirations that Ron Najafi to a science career (05:46)
• Challenges and milestones in building companies like CP Lab Safety and NovaBay Pharmaceuticals (07:59)
• The invention and impact of the ECO Funnel® on lab safety and environmental responsibility (12:01)
• The formation of Emery Pharma following industry setbacks and lessons in adaptation (17:03)
• The fundamentals of impurity risk analysis, especially nitrosamine contamination in pharmaceuticals (20:56)
• The ranitidine (Zantac) NDMA discovery, its investigation, and consequences for drug regulation (23:33)
• Common sources of nitrosamine and practical advice for bioprocess risk management (27:51)
• Differences in impurity risk between small molecule and biologic drug processes (28:03)
• The necessity and regulatory expectation of impurity and leachable/extractable analysis (30:07)

Smart insight:

One of Ron's clients conducted a superficial nitrosamine risk assessment, proceeded to manufacturing, and spent approximately $6 million producing three batches. At final FDA-required testing, NDMA came back at 11,000 nanograms per pill against an acceptable daily intake limit of 96 nanograms. The batches were unusable.

A thorough risk assessment run earlier would have cost a fraction of that. If you are developing a drug with secondary or tertiary amines in your process and have not yet conducted a formal nitrosamine risk assessment, that is the one action to take after listening to this episode.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

• Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing.

Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay development timelines. In his role, Tibor is responsible for the customer interface—spanning sales, service, support, GMP topics, troubleshooting, marketing, and applied technology—with a focus on orbital shaking technology and small-scale cultivation support.

Topics discussed:

• The importance of measuring oxygen transfer rate (OTR) and carbon dioxide transfer rate (CTR) for reproducible bioprocesses—why DO is not sufficient (02:55)
• Real-time process analytical technology (PAT) for small-scale bioreactors, including microtiter plates and shake flasks (06:47)
• Pre-culture reproducibility: transferring at the right OTR and its impact on main cultures (07:56)
• Price sensitivity and scale-up challenges in cultivated meat—implications for media and equipment selection (10:36)
• Expansion of shaking technology to fields such as mixing, storage, and thawing, including applications in liquid crystal production (12:10)
• Leadership lessons from competing with bigger players: how smaller companies stay innovative, agile, and close to their customers (14:20)
• The significance of strong business partner relationships and trusting gut feeling in decision-making (16:32)
• Key advice for smart biotech scientists: careful definition of screening conditions and the use of online measurement tools at small scale (18:09)
• Accessible resources for mastering shaken bioreactor techniques, including webinars and direct contact with Tibor Anderlei (19:38)

Smart insight:

Treat small-scale shaken systems as real bioreactors and define screening conditions carefully from the start. Using online measurement tools even at early stages provides critical visibility and helps ensure that results are reproducible and scalable.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

• Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
• Episode 25 - 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
• Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
• Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?

Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.

Topics discussed:

• Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)
• The gap between educational practices and real-world bioreactor expertise (04:00)
• Tibor Anderlei’s journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)
• Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)
• Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)
• Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)
• Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)
• The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)

Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.

Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

• Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
• Episode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
• Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
• Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show